Ces radiol. 2019, 73(2):71-78 | DOI: 10.55095/CesRadiol2019/011

Magnetic resonance imaging in myocardial amyloidosisReview article

Jiří Ferda1, Jan Baxa1, Milan Hromádka2
1 Klinika zobrazovacích metod LF UK, Plzeň
2 Kardiologická klinika LF UK, Plzeň

Cardiac magnetic resonance (CMR) imaging has an important role in detection and differential diagnosis of the myocardial amyloidosis versus hypertrophic cardiomyopathy, but especially in differential diagnosis of both types of amyloid deposits in the heart muscle - transthyretin amyloidosis (ATTR) and light chain amyloidosis (AL). Because of the most specific test to detect ATTR is scintigraphy, the transmural gradient and gradient apex to base of deposits evaluations are challenging in CMR, the imaging of the involvement in right ventricle and in atria is other important roles of CMR. The imaging techniques of CMR suitable in cardiac amyloidosis assessment are late gadolinium enhancement (LGE) and T1 mapping.

Keywords: cardiac amyloidosis, transthyretin amyloidosis, light-chain amyloidosis, cardiac magnetic resonance
Grants and funding:

Podpořeno projektem MZ ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň a projektem Univerzity Karlovy v Praze Progress q39.

Accepted: February 15, 2019; Published: June 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Baxa J, Hromádka M. Magnetic resonance imaging in myocardial amyloidosis. Ces radiol. 2019;73(2):71-78. doi: 10.55095/CesRadiol2019/011.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Falk RH, Comezo, RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898-909. Go to original source... Go to PubMed...
    2. Emdin M, Aimo A, Rapezzi C, et al. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J 2019 May 20. pii:ehz298. doi:10.1093/eurheartj/ehz298 [Epub ahead of print]. PubMed PMID: 31111153. Go to original source... Go to PubMed...
    3. Slart RHJA, Glaudemans AWJM, Noordzij W, et al. Time for new imaging and therapeutic approaches in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2019; 46(7): 1402-1406. Go to original source... Go to PubMed...
    4. Cappelli F, Gallini C, Perfetto F. PYP or DPD and HDP for cardiac amyloidosis one for all, all for one. J Nucl Cardiol 2019 May 1. doi:10.1007/s12350-019-01728-6 [Epub ahead of print] PubMed PMID: 31044407. Go to original source... Go to PubMed...
    5. Kircher M, Ihne S, Brumberg J, et al. Detection of cardiac amyloidosis with (18)F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging 2019; 46(7): 1407-1416. doi:10.1007/s00259-019-04290-y. Epub 2019 Feb 23. Go to original source... Go to PubMed...
    6. Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: a pilot study using (18)F-flutemetamol positron emission tomography. Ann Nucl Med 2019 May 28. doi:10.1007/s12149-019-01372-7 [Epub ahead of print]. Go to original source... Go to PubMed...
    7. Kim D, Lee GY, Choi JO, et al. Associations of electrocardiographic parameters with left ventricular longitudinal strain and prognosis in cardiac light chain amyloidosis. Sci Rep 2019; 9(1): 7746. doi:10.1038/s41598-019-44245-9. PubMed PMID: 31123293. Go to original source... Go to PubMed...
    8. Sidana S, Tandon N, Gertz MA, et al. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. Br J Haematol 2019; 185(4): 701-707. Go to original source... Go to PubMed...
    9. Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, et al. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Adv 2019; 3(8): 1226-1229. doi:10.1182/bloodadvances.2019032458 Go to original source... Go to PubMed...
    10. Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 2019 May 21. doi:10.1161/CIRCULATIONAHA.118.038169 [Epub ahead of print]. PubMed PMID: 31109193. Go to original source... Go to PubMed...
    11. Michels da Silva D, Langer H, Graf T. Inflammatory and Molecular Pathways in Heart Failure-Ischemia, HFpEF and Transthyretin Cardiac Amyloidosis. Int J Mol Sci 2019; 20(9). pii:E2322. doi:10.3390/ijms20092322.Review. PubMed PMID: 31083399. Go to original source... Go to PubMed...
    12. Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J 2019 Apr 1. pii:ehz173. doi:10.1093/eurheartj/ehz173 [Epub ahead of print]. Go to original source... Go to PubMed...
    13. Fontana M, Banypersad SM, Treibel TA. Differential myocyte responses in patients with cardiac transthyretin Amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 2015; 277: 388-397. Go to original source... Go to PubMed...
    14. Brenner DAJain M, Pimentel DR, et al. Human amyloidogenic ligt-chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circulation Res 2004; 94: 1008-1010. Go to original source... Go to PubMed...
    15. Dungu JN, Valencia O, Pinney JH, et al. CMR-based Differentiation of AL and ATRR cardiac amyloidosis. JACC: Cardiovascular imaging 2014; 7: 133-142. Go to original source... Go to PubMed...
    16. Wan K, Li W, Sun J, et al. Regional amyloid distribution and impact on mortality in light-chain amyloidosis: a T1 mapping cardiac magnetic resonance study. Amyloid 2019; 26(1): 45-51. doi:10.1080/13506129.2019.1578742 [Epub 2019 Apr 1]. Go to original source... Go to PubMed...
    17. White SK, Sado DM, Flett AS, Moon J. Characterizing of the myocardial interstitial space: the clinical relevance of non-invasive imaging. Heart 2012; 98: 773-779. Go to original source... Go to PubMed...
    18. Pelletier-Galarneau M, Abikhzer G, Giraldeau G, Harel F. Molecular Imaging of Cardiac Amyloidosis. Curr Cardiol Rep 2019; 21(3): 12. doi:10.1007/s11886-019-1097-9.Review. Go to original source... Go to PubMed...
    19. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46(6): 1076-1084. Go to original source... Go to PubMed...
    20. Martineau P, Finnerty V, Giraldeau G, et al. Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis. J Nucl Cardiol 2019 Mar 4. doi:10.1007/s12350-019-01675-2 [Epub ahead of print]. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content